Abstract Background/Aims Across various psoriatic arthritis (PsA) management guidelines (BSR, EULAR, GRAPPA) a consistent theme is the importance of multispecialty (involving other medical disciplines) and multidisciplinary (involving nurses, physiotherapists, psychologists, etc.) care. However, service-level aspects of care are poorly defined, with limited evidence-based guidance on service organisation, accessibility, or quality. This study aimed to describe key organisational features of PsA care, and to explore whether patient outcomes were better among those managed in services with access to multispecialty clinics. Methods The British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA) recruits patients from 82 UK centres. In March 2025, each was asked to complete an online survey about aspects of service delivery including multispecialty involvement - and which specialties. Patient-level data was available BSR-PsA participants at the time of recruitment. Those recruited within 1yr of diagnosis were excluded. Patient outcomes were compared between centres that had access to multispecialty clinics, versus those that did not, using simple descriptive statistics. Results Fifty-one centres (62%) completed the survey, including 24 teaching hospitals, 23 district generals, and 2 tertiary referral centres. Twenty-nine (57%) services cared for 500 PsA patients, including 11 (22%) with 1000. Twenty-eight (55%) had 5 whole-time equivalent (WTE) rheumatology consultants, and all reported specialist nurse involvement; 31% reporting 5 WTEs. However, five centres (10%) had no access to any MDT meetings (including rheumatology-only MDTs) to discuss and plan PsA patient care. Nineteen centres (37%) held multispecialty clinics with dermatology. Eight (42%) also involved ophthalmology and/or gastroenterology. From participating centres, data were available from 1109 BSR-PsA participants; 43% commencing b/tsDMARDs, and 57% b/tsDMARD-naïve. There was consistent evidence that participants from centres with access to multispecialty clinics experienced significantly better disease outcomes (Table 1). These differences are partly explained by variation in the proportion of patients starting b/tsDMARDs, but this did not fully account for differences in outcomes. Conclusion We have shown a number of differences in key service components among centres recruiting to the BSR-PsA. Importantly, patients cared for in services with access to multispecialty clinics had better outcomes. This provides, for the first time, an evidence base to support service reconfiguration to improve PsA care. Disclosure G.T. Jones: Honoraria; GTJ has received honoraria from Janssen and UCB. Grants/research support; GTJ has received research funding (paid to employer) from AbbVie, Amgen, GlaxoSmithKline, Menarini, Pfizer, Shionogi and UCB. R. MacDonald: None. J. Payne: None. H. Abdel-Fattah: None. Z. Muhammad: None. G.J. Macfarlane: Consultancies; GJM has been on an advisory board for UCB. Grants/research support; GJM has received research funding (paid to employer) from AbbVie, Amgen, GlaxoSmithKline, Menarini, Pfizer, Shionogi and UCB. R.J. Hollick: Honoraria; RJH has received honoraria from CSL Vifor. Other; RJH has received travel support from Fresenius Kabi.
Jones et al. (Wed,) studied this question.